ES Foundry's Alex Zhu outlines how the US cell maker is betting on PERC while navigating shifting regulations and supply-chain constraints.

It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

HEFEI, ANHUI, CHINA, January 19, 2026 /EINPresswire.com/ — The global photovoltaic (PV) industry is entering a phase defined less by headline capacity additions and ...

While Kite Pharma has partnered with Cytiva to develop a new cell therapy manufacturing platform, which was rolled out last month, the Gilead Sciences subsidiary isn’t stopping there in its pursuit of ...

Japanese PV manufacturer Toyo has reported 2.6GW of cell shipments and 191.5MW of module shipments in the first half of 2026.

Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The 71-year-old grandfather with metastatic melanoma had flown in from ...

In just a year, ALMM-listed solar PV cell manufacturing capacity has increased from around 13 GW to roughly 31 GW across eight revisions. With a substantial pipeline of commissioned, ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...